Stifel Maintains Buy on Zentalis Pharma, Raises Price Target to $50
Portfolio Pulse from jenniferd'souza@benzinga.com
Stifel analyst Bradley Canino maintains a Buy rating on Zentalis Pharma (NASDAQ:ZNTL) and raises the price target from $45 to $50.
June 07, 2023 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino maintains a Buy rating on Zentalis Pharma and raises the price target from $45 to $50.
The news of Stifel maintaining a Buy rating and raising the price target for Zentalis Pharma (ZNTL) from $45 to $50 is positive for the stock. This indicates that the analyst has confidence in the company's growth potential and expects the stock price to rise in the short term. As a result, this news is likely to have a positive impact on ZNTL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100